United States: Federal Court Rejects HHS Interpretation Of 340B Program's Orphan Drug Rule

On October 14, 2015, the United States District Court for the District of Columbia (the Court) issued a decision in Pharmaceutical Research and Manufacturers of America v. United States Department of Health and Human Services, et al. In this case, Pharmaceutical Research and Manufacturers of America (PhRMA) challenged interpretive guidance issued by the Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Resources, pertaining to the 340B Drug Pricing Program's (340B Program) so-called "orphan drug exclusion." In sum, the Court found HRSA's interpretive guidance to be contrary to the plain language of the 340B statute.

The Court's opinion follows an earlier decision from 2014 ( see here), in which the Court held that HRSA did not have the requisite statutory authority to issue formal rules on the subject of the orphan drug exclusion.

The 340B Program allows certain providers (Covered Entities) to purchase "covered outpatient drugs" from drug manufacturers at discounted prices. The Affordable Care Act (ACA) extended eligibility to participate in the 340B Program to certain additional types of hospitals (including critical access hospitals, sole community hospitals, rural referral centers and freestanding cancer hospitals). The ACA also added a provision to the 340B statute (codified at 42 U.S.C. § 256b(e)), applicable only to those newly eligible hospitals, that specifically excluded from the definition of "covered outpatient drugs" certain drugs designated by the U.S. Food and Drug Administration (FDA) for a rare disease or condition (orphan drugs). As a result of this "orphan drug exclusion," those newly eligible hospitals are unable to purchase orphan drugs at the 340B price.

As noted briefly above, HRSA previously sought to issue a formal rule interpreting the orphan drug exclusion. HRSA's formal rule provided that affected hospitals that track drugs by indication could purchase orphan drugs at the 340B price if such drugs were to be used for non-orphan indications. If the drugs were to be used for orphan indications, or if an affected hospital did not track drugs by indication, then orphan drugs could not be purchased at the 340B price.  Thus, those affected hospitals were able to purchase orphan drugs at the 340B price where such orphan drugs were to be used for non-orphan indications. In the 2014 opinion referenced above, the Court held that HRSA did not have the requisite statutory authority to issue a formal rule interpreting the orphan drug exclusion. Notably, in that 2014 decision, the Court did not give an opinion on the validity of HRSA's interpretation of the orphan drug exclusion.

Following the 2014 decision, HRSA reissued the content of the formal rule — specifically, that ACA-eligible hospitals could purchase orphan drugs at 340B prices if the drugs were to be used for non-orphan indications — as interpretive guidance (Orphan Drug Guidance). PhRMA again brought suit against HRSA, this time challenging the substance of the Orphan Drug Guidance.

At the outset of its decision, the Court acknowledged HRSA's authority to generally interpret the 340B statute, and to make public its interpretations through guidance. Prior to ruling on the substance of the Orphan Drug Guidance, the Court made a threshold determination that the guidance was a "final agency action" and therefore was subject to judicial review. To arrive at this conclusion, the Court found that (i) the Orphan Drug Guidance was clearly the "consummation" of HRSA's decision-making process, and was not tentative or interlocutory in nature; and (ii) that the Orphan Drug Guidance would create legal rights and consequences for drug manufacturers. In finding that the Orphan Drug Guidance would in fact create legal rights and consequences, the Court rejected HRSA's argument that since HRSA had not yet enforced the requirements of the Orphan Drug Guidance against any drug manufacturer, that no legal rights had been created by the guidance. The Court acknowledged that so-called "pre-enforcement" challenges to agency review were legally acceptable in certain instances, and found that the Orphan Drug Guidance was subject to challenge despite the fact that HRSA had not yet undertaken any enforcement activities for noncompliance with the Orphan Drug Guidance.

After determining that the Orphan Drug Guidance was a "final agency action" subject to judicial review, the Court sought to determine whether the substance of the guidance was a valid interpretation of the 340B statute. After weighing the appropriate level of deference to be given to HRSA's interpretation, the Court concluded that HRSA's orphan drug guidance was "contrary to the plain language of section 340B(e)." In reaching this conclusion, the Court looked to the language of the statute, which states the orphan drug exclusion applies to those drugs that are "designated... for a rare disease or condition." Although acknowledging that HRSA's interpretation "might appear plausible at first glance, and when confined solely to section 340B(e)," the Court examined the interpretation in the context of related provisions of federal law. Thereafter, the Court pointed out that in related areas of federal law, language is used to differentiate specifically the use of a drug and such drug's designation as an orphan drug. Since Section 340B(e) does not include such differential language, the Court concluded that the statute would not permit HRSA's interpretation that drugs which have orphan designations but are not used for the rare disease or condition for which the designation was made, could be purchased at the 340B price.

In light of the Court's decision to invalidate HRSA's Orphan Drug Guidance, it is possible that HRSA will be vulnerable to legal challenges to its recently issued proposed omnibus guidance related to the 340B Program. Such proposed omnibus guidance covers a wide array of 340B Program topics, including definitions of eligible "patient" and eligible "covered outpatient drugs" as well as guidance pertaining to the group purchasing organization (GPO) prohibition and Medicaid managed care prescriptions. (For further discussion, see here.) It is important to note, however, that the proposed omnibus guidance has been issued pursuant to a more formal notice and comment process and as such may be accorded more judicial deference than the Orphan Drug Guidance. The Court decision does, however, bring to the forefront the ability of affected 340B Program participants (covered entities and drug manufacturers alike) to challenge portions of the proposed omnibus guidance with which such participants disagree. 

Since the Court issued its decision, HRSA has removed the Orphan Drug Guidance from its website. At this time, it is unclear as to how HRSA will approach compliance with the orphan drug exclusion.

Federal Court Rejects HHS Interpretation of 340B Program's Orphan Drug Rule

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions